Eribulin exerts its pharmacologic effects by binding to the plus ends of microtubules and suppressing microtubule growth, without affecting microtubule shortening, and by inducing the formation of ...

"Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers" was originally created and published by Pharmaceutical ...